Navigation Links
Study shows botanical formula fights prostate cancer
Date:4/10/2012

A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells. The study also demonstrated the formula has no toxic side effects, even at high dosages.

"This study is a milestone in the research of this formula, demonstrating its safety and effectiveness in treating human prostate cancer in an animal model," says researcher and formula inventor Dr. Isaac Eliaz. "These positive results offer a significant contribution to prostate cancer research and add to the growing body of published data substantiating the role of natural compounds in the treatment of prostate cancer."

The formula combines botanical extracts, phytonutrients, botanically-enhanced medicinal mushrooms and antioxidants. This is the third study from a major university to demonstrate the formula's ability to suppress tumor growth and metastasis. For more information on the formula, visit www.prostatehealthsolutions.org.

"Multiple studies have demonstrated that this prostate formula is a possible treatment for hormone-refractory prostate cancer," says lead researcher, Dr. Daniel Sliva.

The study found that the orally-administered formula suppressed tumor growth by 27 percent, compared to controls. In addition to significant reduction in tumor volume, the formula inhibited several genes (IGF2, NRNF2 and PLAU/uPA) that encourage cancer proliferation and metastasis. The formula also increased expression of CDKN1A, a gene that fights prostate cancer by inhibiting cancer-promoting cellular mechanisms.

By suppressing genes related to aggressive prostate cancer growth and proliferation, and increasing the expression of cancer-fighting genes, the formula demonstrates multiple anti-cancer mechanisms and genetic targets.

This pre-clinical in vivo study confirms previously published in vitro data, which showed the formula decreases the expression of PLAU/uPA genes in aggressive, hormone-independent prostate cancer cells.

Prior to this research, the formula was studied at Columbia University and the Cancer Research Laboratory, Methodist Research Institute, at Indiana University Health. These studies also showed the formula inhibits prostate cancer growth and proliferation.


'/>"/>

Contact: Amy Pellegrini
amy@dreliaz.org
707-583-8622
Better Health Publishing
Source:Eurekalert

Related biology news :

1. Approach to diabetes self-management too narrow, study suggests
2. Study finds peoples niceness may reside in their genes
3. Loyola study debunks common myth that urine is sterile
4. UCSB study shows forest insects and diseases arrive in US via imported plants
5. Head and body lice appear to be the same species, genetic study finds
6. Life expectancy may affect when you get married, divorced, have kids: Queens University study
7. Sexual reproduction brings long-term benefits, study shows
8. Researchers use game to change how scientists study disease outbreaks
9. Copper chains: Study reveals Earths deep-seated hold on copper
10. Study shows unified process of evolution in bacteria and sexual eukaryotes
11. Scientists study the catalytic reactions used by plants to split oxygen from water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... NDA Partners Chairman ... former Acting Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, and ... the company as an Expert Consultant. , In Dr. Spyker’s accomplished career, he ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 /PRNewswire/ ... today expansion of its translational research program using ... establishment of laboratory facilities in San Diego.  The ... Diego BioLabs facility, a biotechnology incubator sponsored by ... In November 2016, the Company obtained ...
(Date:2/22/2017)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results ... 2016. "Our annual 2016 financial results ... billion and earnings exceeded $700 million," said Martine ... Officer. "These financial results strengthen our ability to ...
Breaking Biology Technology: